<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04403568</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20190735H</org_study_id>
    <nct_id>NCT04403568</nct_id>
  </id_info>
  <brief_title>Testing the Synergism of Phytonutrients, Curcumin and Ursolic Acid, to Target Molecular Pathways in the Prostate</brief_title>
  <official_title>Phase I Clinical Trial Testing the Synergism of Phytonutrients, Curcumin and Ursolic Acid, to Target Molecular Pathways in the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A proof of concept clinical trial to assess the synergism of curcumin (CURC) and ursolic acid&#xD;
      (UA). Before further testing within formal cancer clinical trials, we must (1) evaluate the&#xD;
      bioavailability and safety, (2) confirm the presence of metabolites in the target organ, and&#xD;
      (3) validate the appropriate mechanism of effect&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Once a subject is identified that may meet eligibility criteria, the physician and/or study&#xD;
      investigators will be alerted to the potential candidate and will introduce the study to the&#xD;
      patient at their standard of care (SOC) appointment or via telephone. Patients will be given&#xD;
      the option for enrollment and if they agree, informed consent will be discussed and obtained&#xD;
      provided they meet all inclusion/exclusion criteria. Following informed consent, subjects&#xD;
      will be assigned to one of the following cohorts:&#xD;
&#xD;
      Cohort 1:&#xD;
&#xD;
      • Ursolic Acid (150 mg) BID (twice a day)&#xD;
&#xD;
      Cohort 2:&#xD;
&#xD;
      • Curcumin (600 mg) BID&#xD;
&#xD;
      Cohort 3:&#xD;
&#xD;
      • Ursolic Acid (150 mg) and Curcumin (600 mg) BID&#xD;
&#xD;
      The study team aim to enroll 10 subjects who will complete the study into each cohort for a&#xD;
      total of 30 completers. Subjects will be enrolled on a rolling basis with the first ten&#xD;
      subjects assigned to Cohort 1, the next ten subjects assigned to Cohort 2, and the last 10&#xD;
      subjects assigned to Cohort 3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No subjects were enrolled in this study, the PI will seek funding and revise the protocol for&#xD;
    resubmisson at a later date&#xD;
  </why_stopped>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Subjects will be assigned to one of 3 cohorts, starting with cohort 1 and progressing to cohort 3</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number, frequency, duration, and relation of toxicity events</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Safety will be compared to evaluate the number, frequency, duration, and relation of toxicity events to CURC/UA combination, as defined by the Common Terminology Criteria for Adverse Events (CTCAE) v 4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak serum concentration</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Dose response curve representing the pharmacokinetic parameter peak serum concentration (Cmax) of ursolic acid, curcumin, and their metabolites will be graphed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach peak serum concentration</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>The pharmacokinetic parameter, the area under the curve (Tmax) representing the time it takes to reach Cmax of ursolic acid, curcumin, and their metabolites will be graphed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>The pharmacokinetic parameter, half-life of ursolic acid, curcumin, and their metabolites will be graphed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of UA, CURC, and metabolites in prostate tissue</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Identify the presence and levels of UA, CURC and their metabolites in prostate tissue using HPLC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunohistochemistry measurement</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Immunohistochemistry of proportion of nuclear p65 NFkB staining before and after prostatectomy on FFPE samples will be completed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Ursolic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of Ursolic Acid to subjects who are scheduled to undergo radical prostatectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of Curcumin to subjects who are scheduled to undergo radical prostatectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ursolic Acid and Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of Ursolic Acid and Curcumin to subjects who are scheduled to undergo radical prostatectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursolic Acid</intervention_name>
    <description>Ursolic Acid 150mg</description>
    <arm_group_label>Ursolic Acid</arm_group_label>
    <arm_group_label>Ursolic Acid and Curcumin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Curcumin 600mg</description>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_label>Ursolic Acid and Curcumin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have proven diagnosis of prostate cancer with Gleason Group 3 or lower and planning to&#xD;
             undergo radical prostatectomy&#xD;
&#xD;
          -  Be able to give informed consent&#xD;
&#xD;
          -  Be age 18 or older&#xD;
&#xD;
          -  Able to stop supplements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Age &lt; 18&#xD;
&#xD;
          -  High-risk prostate cancer or suspected metastasis&#xD;
&#xD;
          -  Unable to swallow pills&#xD;
&#xD;
          -  Unable to stop supplements&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Liss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mays Cancer Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 21, 2020</study_first_submitted>
  <study_first_submitted_qc>May 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radical Prostatectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursolic acid</mesh_term>
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data will be available upon request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>De-identified individual participant data will be available upon completion of the study for approx. 1 year.</ipd_time_frame>
    <ipd_access_criteria>Access granted upon request.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

